Fibrosis in non-responders to Interferon

TITLE: Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years

Abstract:
In chronic hepatitis C, previous data have shown that short-term treatment with interferon-alpha (IFN-alpha) can reduce collagen deposition in the liver independently of the viral response.

The aim of this work was to determine, in non-responder patients, the longterm effect of IFN-alpha on liver fibrosis according to the total administered dose and the fibrotic stage. Fibrosis was investigated on liver biopsies from 24 non-responder patients with chronic hepatitis C retreated with successive courses of IFN-alpha. The degree of liver fibrosis was assessed on three successive biopsies, performed before IFN-alpha treatment and 1 and 5 years later, in 13 and 11 patients, respectively, treated for less (mean: 7.5 months, 313 MU) and more (mean: 21.8 months, 791 MU) than 1 year, For each biopsy, fibrosis was assessed using a histological semiquantitative fibrosis scoring system and by morphometry after picrosirius red staining, Regardless of the dose and duration of IFN-alpha therapy, a slight decrease of fibrosis was observed in patients 5 years after starting treatment, In cirrhotic patients, a short treatment induced an improvement followed by a relapse of fibrosis in 57%, and only 43% of patients showed constant collagen regression over the 5 years of follow-up. On the contrary, after prolonged therapy, a progressive and significant decrease occurred throughout the follow-up period in all patients (P = 0,045).

Long-term treatment with IFN-alpha is therefore associated with regression of liver fibrosis particularly in cirrhotic patients. These promising results need to be confirmed in a larger series of patients.

AUTHOR: Guerret S, Desmouliere A, Chossegros P, Costa AMA, Badid C, Trepo C, Grimaud JA, Chevallier M
SOURCE: JOURNAL OF VIRAL HEPATITIS 6: (2) 125-133 MAR 1999

Who Will Respond to Hepatitis C Treatment
The relatively new field of proteomics may be able to predict who will respond to Hepatitis C therapy - before treatment even begins....

Antivirals Combined Without Interferon: New Trial
Three companies unite to begin an innovative Hepatitis C trial, where two oral antiviral drugs will be combined in the absence of interferon....

HCV May Be Able to Be Cleared from Both Blood and Liver
Viral clearance doubled in a Hepatitis C Phase II trial during standard therapy when coupled with GlobeImmune's GI-5005. Because Hepatitis C must be eradicated not just from the blood, but also the liver, GI-5005's ability to speed the clearance rate...